<DOC>
	<DOCNO>NCT01649921</DOCNO>
	<brief_summary>The primary aim study assess effect adjunctive therapy Interferon ( IFN ) -gamma immune function patient septic shock placebo-controlled manner . Moreover , investigator want evaluate new marker could use identify patient immunoparalysis , monitor patient 's immunological response IFN-γ . In addition , mechanistic study perform elucidate mechanism ( epigenetic modification ) behind immunoparalysis effect IFN-γ mechanism . With use result investigator obtain pilot study , investigator conduct large multicentre clinical trial IFN-γ .</brief_summary>
	<brief_title>The Effects Interferon-gamma Sepsis-induced Immunoparalysis</brief_title>
	<detailed_description>Sepsis lead cause death ICU estimate 6 million victim per year worldwide . Although septic shock traditionally view excessive systemic inflammatory reaction invasive microbial pathogen , pharmacological suppression innate immune response sepsis prove unsuccessful . An important reason might vast majority septic patient survive initial pro-inflammatory hit , die subsequent immunosuppressed state due secondary/opportunistic infection . This so-called 'immunoparalysis ' increasingly recognize override immune dysfunction septic patient . Reversal sepsis-induced immunoparalysis therefore promising adjunctive treatment patient present septic shock . It demonstrate interferon-gamma ( IFN ) -gamma reverse immunoparalysis vitro vivo animal healthy volunteer . Moreover , case-series septic patient interferon-gamma treatment lead reversal immunoparalysis , reduction mechanical ventilation time length stay relevant side-effects . The primary aim study assess effect adjunctive therapy IFN-gamma immune function patient septic shock placebo-controlled manner . Moreover , investigator want evaluate new marker could use identify patient immunoparalysis , monitor patient 's immunological response IFN-γ . In addition , mechanistic study perform elucidate mechanism ( epigenetic modification ) behind immunoparalysis effect IFN-γ mechanism .</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Shock , Septic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Inclusion criterion : Written inform consent patient legal representative Age &gt; 18 year Presence septic shock bacterial origin evidence bacterial infection ( last 96 hour , least one pathogenic microorganism blood , sputum , urine , normally sterile body fluid , central venous catheter ; Focus infection identify ( e.g . rupture bowel , purulent drainage/sputum ) ; leukocytes normally sterile body fluid ) , Two SIRS criterion ( last 24 hour , fever ( &gt; 38.3 ˚C ) , hypothermia ( &lt; 35.6 ˚C ) , tachycardia ( &gt; 90bpm ) , tachypnea ( &gt; 20/min ) , partial pressure arterial carbon dioxide ( PaCO2 ) &lt; 32 mmHg , mechanical ventilation , leukocytosis ( &gt; 12,000/μl ) , leucopenia ( &lt; 4,0000/μl ) , &gt; 10 % immature form ) , presence shock need vasopressor therapy maintain systolic blood pressure ( SBP ) ≥ 90 mmHg . Pregnancy lactate Subjects history allergy intolerance IFNgamma Systemic autoimmune disease , hematologic disease ( neoplasma , acute leukemia ) , transplant patient , patient steroid medication receive prednisolone equivalent &gt; 5 mg per day Human immunodeficiency virus positivity Presence advance directive withhold withdraw life sustain treatment Underlying disease prognosis survival &lt; 3 month , moribund patient highly likely die within 24 hour . Cardiopulmonary resuscitation ( &lt; 72 hour ) enrollment Acute myocardial infarction pulmonary embolization ( &lt; 72 hour ) Participation clinical trial 30 day prior inclusion Subjects history document epileptic seizure Subjects severe renal impairment ( creatinine clearance le 30 mL/min ) Subjects severe liver failure ( impaired synthesis proteins coagulation factor manifest increased prothrombin time ) Subjects absolute neutrophil count le 500/mm3 study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Sepsis</keyword>
	<keyword>SIRS</keyword>
	<keyword>Septic shock</keyword>
	<keyword>Immunoparalysis</keyword>
	<keyword>Interferon-gamma</keyword>
</DOC>